Abstract
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are causative agents of acute viral hepatitis transmitted via the fecal–oral route. Both viruses place a heavy burden on the public health and economy of developing countries. To test the possibility that HAV could be used as an expression vector for the development of a combination vaccine against hepatitis A and E infections, recombinant HAV-HEp148 was created as a vector to express an HEV neutralization epitope (HEp148) located at aa 459–606 of the HEV capsid protein. The recombinant virus expressed the HEp148 protein in a partially dimerized state in HAV-susceptible cells. Immunization with the HAV-HEp148 virus induced a strong HAV- and HEV-specific immune response in mice. Thus, the present study demonstrates a novel approach to the development of a combined hepatitis A and E vaccine.
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 260 |
| Zeitschrift | Viruses |
| Jahrgang | 9 |
| Ausgabenummer | 9 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 15.09.2017 |
Fördermittel
Conflicts of Interest: No conflicting financial interests exist. This work was supported by grant (2016-I2M-1-019) from the CAMS Initiative for Innovative Medicine and Science and Technology Plan Project of Yunnan Province (2014BC008; 2016FB034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
